Format

Send to

Choose Destination
J Microbiol Immunol Infect. 2013 Feb;46(1):65-7. doi: 10.1016/j.jmii.2011.12.020. Epub 2012 May 22.

Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis.

Author information

1
Division of Allergy and Immunology and Rheumatology, Chang Gung Memorial Hospital, Chia-yi, Taiwan.

Abstract

The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA), and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in patients with lymphoma. However, there have been no papers detailing hepatitis C virus reactivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of liver function and viral load is mandatory after RTX therapy in patients with RA and concomitant hepatitis C.

PMID:
22627098
DOI:
10.1016/j.jmii.2011.12.020
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center